Introduction
The infantile form of Pompe disease (acid maltase deficiency; glycogen storage disease type II; MIM 232300) is a progressive, lethal metabolic myopathy. Pompe disease is characterized by the massive accumulation of lysosomal glycogen in striated muscle, with an accompanying disruption of cellular functions. Infantileonset Pompe disease causes death early in childhood from cardiorespiratory failure related to an underlying hypertrophic cardiomyopathy 1 Late-onset forms of Pompe disease feature progressive weakness without significant cardomyopathy, and patients with juvenileonset Pompe disease typically become ventilator dependent because of respiratory muscle involvement.
Pompe disease results from the inherited deficiency of lysosomal acid-a-glucosidase (GAA; acid maltase; EC 3.2. 1.20) . Currently, enzyme replacement therapy (ERT) has received marketing approval in Pompe disease. ERT in Pompe disease is facilitated by mannose-6-phosphate receptor-mediated uptake of the 110 kDa precursor GAA. [1] [2] [3] The limitations of ERT in Pompe disease include humoral immunity, the requirement for high dosages to achieve efficacy and the high frequency of intravenous (IV) infusions. 4, 5 In clinical trials of ERT in Pompe disease, up to 40 mg kg À1 of hGAA was required to improve clinical end points in clinical trials. [6] [7] [8] High-titer anti-GAA antibody formation has been demonstrated in Pompe patients who lacked any residual GAA protein, termed cross-reacting immune material negative (CRIM-negative). Neutralizing antibodies occurred in CRIM-negative Pompe disease patients, and markedly reduced the efficacy of ERT in these subjects. 6, 7, 9 Thus, other therapeutic approaches such as gene therapy are under development for Pompe disease.
The strategy of liver-targeted gene therapy in Pompe disease depends upon the conversion of the liver into a depot for GAA production. The liver secreted GAA into circulating blood, similar to injections of recombinant GAA during ERT, which will be taken up by affected muscles to correct glycogen storage. Hepatic expression of human GAA has achieved a moderate degree of efficacy in mouse models. [10] [11] [12] This strategy was limited in some experiments by anti-GAA antibody formation, accompanied by markedly reduced efficacy. 10, 11 However, adeno-associated virus (AAV) vectors containing a liver-specific promoter induced immune tolerance against hGAA in GAA-KO mice and efficiently cleared glycogen in cardiac muscle and the majority of skeletal muscles. [10] [11] [12] The overexpression of hGAA in liver might not be ideal, because the liver is not a therapeutic target and biochemical correction of striated muscles has been inconsistent in proof-of-concept experiments. Uptake of GAA has been reduced at least in part by downregulation of the cation-independent mannose-6-phospahte receptor in type II myofibers, which leads to incomplete clearance of accumulated glycogen in the striated muscles by ERT or hepatic expression of GAA. 5 Muscle-targeted gene therapy might be a more efficient approach to gene therapy in Pompe disease. Muscle-restricted transgene expression with a musclespecific expression cassette has evaded transgenedirected immune responses; furthermore, this strategy reduced glycogen accumulations in the heart to nearnormal levels, and to a lesser extent in skeletal muscle. 13, 14 The ideal approach might be to inject an AAV vector intravenously to transduce muscle widely with a muscle-specific transgene. Although AAV vectors have delivered genes to striated muscle following IV administration, achieving efficacy without disrupting vascular integrity depended upon the administration of very high numbers of vector particles, 14, 15 which might not be feasible clinically because of the limits imposed by limitations of production and potential T cell responses against the vector capsid proteins. 16 One strategy that might reduce the number of vector particles required to transduce skeletal muscle is isolated limb perfusion (ILP), which has the potential to correct multiple limb muscles with lower number of vector particles. 17, 18 ILP involves the rapid injection of a plasmid or viral vector whereas a proximal tourniquet occludes venous drainage of the limb, which creates sufficient pressure to disrupt vascular integrity and to release the vector solution into surrounding muscle. Originally developed in rat models with plasmid DNA, this method has been adapted to the delivery of viral vectors in larger animal models, and enhanced transduction of limb muscles was demonstrated with AAV vectors in comparison with low-pressure IV infusion. [17] [18] [19] The widespread transduction of skeletal muscle following hydrostatic ILP suggested that this approach might be advantageous for the development of muscle-targeted gene therapy in Pompe disease.
We have evaluated the relative efficacy of low-dose AAV vector-mediated GAA expression in mice with Pompe disease, administered either by IV injection or hydrostatic ILP. The number of vector particles administered (1 Â 10 11 ) previously failed to achieve biochemical correction of hindlimb muscles following IV injection with the AAV2/8 vector evaluated, an highly efficacious AAV2/9 vector was administered at even lower dose (3 Â 10 10 ), to test the limits of efficacy for ILP in this study.
Results
Systemic correction of skeletal muscles in GAA-KO mice required IV administration of a very high number of AAV vector particles. 14 In order to increase transduction of hindlimb muscles with fewer vector particles, an AAV vector containing the highly active muscle-specific MHCK7 regulatory cassette to drive human placental alkaline phosphatase (AP) expression was administered by ILP. 20 AP staining demonstrated widespread transduced myofibers in the quadriceps, gastrocnimus and extensor digitorum longus (EDL) muscle following ILP administration. IV administration of the equivalent number of vector particles resulted in much less transduction of skeletal muscles and much more transduction of cardiac muscle, in comparison with ILP administration (Figure 1 ).
We next confirmed that ILP of the AAV2/8 vector greatly increased AAV transduction and GAA expression in multiple hindlimb muscles of GAA-KO mice. AAV-MHCK7hGAApA, which contains the MHCK7 regulatory cassette to drive human GAA expression, was packaged as AAV2/8 and administered to 3-month-old GAA-KO mice by hydrostatic ILP or IV injection, and control mice were administered PBS by ILP injection. Eighteen weeks following vector administration, high levels of GAA expression were detected in multiple limb muscles including the gastrocnemius, soleus, EDL and quadriceps, in ILP vector-injected mice (Figure 2a ). The efficiency of ILP administration was higher in three out of six GAA-KO with lower glycogen content in the gastrocnemius, and the ILP results were sorted into two groups accordingly ( Figure 2b ; ILP, high vs low; P ¼ 0.049). Biochemical correction was confirmed by demonstrating that glycogen reduction was marked following ILP in the hindlimb muscles, including gastrocnemius (64%), soleus (70%), EDL (38%) and quadriceps (43%), in comparison with PBS-injected GAA-KO mice.
In contrast, the IV-injected mice were found to have elevated GAA activity only in the heart, not in skeletal (Figure 2a ). Glycogen content was not reduced in the hindlimb muscles following IV administration, in comparison with PBS-injected GAA-KO mice (Figure 2b ). Furthermore, glycogen content was reduced to a greater extent following ILP in comparison with IV administration in quadriceps (P ¼ 0.02), soleus (P ¼ 0.01) and EDL (P ¼ 0.03) ( Figure 2b ). The mean glycogen content of gastrocnemius for the higher efficiency ILP group (ILP high) was significantly reduced in comparison with the IV group (P ¼ 0.008); however, combining the results for all ILP-treated mice did not reveal significantly reduced glycogen content in the gastrocnemius in comparison with the IV group (P ¼ 0.06). The differing response between ILP high and low groups reflected variations in transduction efficiency with hydrostatic ILP over the course of the initial experiment, which did not preclude significantly improved biochemical correction in the majority of the skeletal muscles analyzed over that achieved by IV administration. Differences in anti-GAA antibody levels were detected by enzyme-linked immunosorbent assay between groups of GAA-KO mice following ILP and IV injections. The antibody levels were higher in ILP-injected mice when compared with IV-injected mice, and did not interfere with efficacy in terms of biochemical correction of striated muscle ( Figure 2c ). Furthermore, efficacy in skeletal muscle did correlate with vector genome quantification. For gastrocnemius, vector genomes were increased following ILP administration, in comparison with IV administration (0.11 ± 0.05 vs 0.001 ± 0.001, respectively), as quantified by real-time PCR.
The pattern of GAA expression was further confirmed by western blot analysis of muscles from each group following AAV2/8 vector administration (Figure 3 ). Glycogen staining revealed glycogen clearance in most myofibers in the gastrocneminus of the ILP vectorinjected mouse (Figure 4 ). Despite the presence of anti-GAA antibodies in all vector-injected mice (not shown), long-term GAA expression and glycogen clearance was achieved in AAV-transduced muscle cells.
Subsequently, the number of vector particles was further reduced to evaluate the efficacy of ILP at a lower dose. Previously, AAV2/9 was deemed a more efficient pseudotype for the correction of skeletal muscle than AAV2/8 in GAA-KO mice. 14 The AAV2/9 vector was administered at a lower dose (3 Â 10 10 v.p.), either by ILP or IV administration. Immune responses that might reduce efficacy were prevented by treating the tolerant GAA-KO mouse strain. GAA-KO mice were previously rendered immune tolerant to human GAA through the insertion of a low-expressing liver-specific transgene that prevented antibody formation in response to long-term ERT, 5 Immune tolerant GAA-KO mice would be anticipated to achieve a higher degree of efficacy from a given dose of AAV vector, because of the potential for secretion of GAA from transduced myofibers and the receptormediated uptake of GAA by non-transduced myofibers. Initially, the absence of antibody formation was confirmed by persistent expression of GAA in plasma in vector-treated mice as detected by western blot (not shown). Consistent with earlier results, ILP administration significantly increased the GAA activity of hindlimb muscles other than quadriceps (Po0.05), in comparison with IV administration (Figure 5a ). All mice treated with ILP responded demonstrated similarly reduced glycogen content in the hindlimb muscle during the second Figure 5b ). However, IV administration significantly elevated GAA activity (P ¼ 3 Â 10 À8 ) and reduced glycogen content in the heart (P ¼ 0.0007) in comparison with ILP administration ( Figure 5 ), confirming the advantage of systemic delivery with regard to correction of cardiac muscle.
Discussion
Previously, we have demonstrated that muscle-targeted gene therapy is an effective approach for the treatment of GAA-KO mice. 13, 14 Muscle-restricted expression of hGAA with an AAV vector containing a muscle-specific promoter provoked only a humoral, but not a cellular immune response in GAA-KO mice by the evidence of a lack of lymphocytic infiltrates and absence of CD8+ lymphocytes in the injected muscle. 13 However, systemic correction of muscle glycogen content requires IV administration of a very high number of AAV vector particles. 14 The adaptation of ILP for muscle-targeted gene therapy in the mouse model has currently demonstrated biochemical correction of GAA deficiency and glycogen storage in hindlimb muscles at a much lower vector dose. Previously, a 10-fold higher number of AAV2/8 vector particles achieved similar levels of biochemical correction in skeletal muscles, and the lower number of vector particles administered in this study has been consistently inefficacious when administered by the IV route. 14 Although the threefold lower number of AAV2/9 vector particles failed to express GAA as highly or reduce glycogen accumulations as effectively in a second experiment, the principle of higher efficiency transduction of skeletal muscle with fewer vector particles using ILP has now been convincingly established in the GAA-KO mouse model for Pompe disease.
The main limitation of ILP is a lack of cardiac muscle transduction, which would be required to achieve efficacy in the severe form of Pompe disease, as it would be in many inherited metabolic myopathies and muscular dystrophies. The simple innovation of administering vector by both ILP and IV routes has been demonstrated with an AAV2/6 vector encoding a histochemical marker protein in a canine model. 21 The immune tolerant mouse strain used for the AAV2/9 study was derived by introducing a lowexpressing liver-specific transgene to achieve immune tolerance to human GAA. 5 These immune tolerant GAA-KO mice are similar to a subgroup of patients with Pompe disease who synthesize a non-functional form of native enzyme that can be detected immunologically, and such patients are deemed CRIM-positive. 9 CRIMpositive patients with Pompe disease do not form anti-GAA antibodies when exposed to human GAA via ERT. We did not intend to compare efficacy of AAV2/8 and AAV2/9 in this study; however, we attempted to optimize GAA transduction of skeletal muscle by using the immune tolerant GAA-KO mice in the AAV2/9 experiment to determine: (1) if secretion of hGAA would be achieved from AAV-transduced muscles and (2) if the secreted GAA in blood would correct heart glycogen storage through enzyme uptake. Although the secretion of GAA in these mice was confirmed by western blot analysis of plasma (data not shown), heart glycogen level was not reduced following hydrostatic ILP delivery of the AAV2/9 vector in immune tolerant GAA-KO mice. The latter data indicated that a high number of AAV2/9 Figure 4 Glycogen staining of skeletal muscle. Periodic acid/Schiff staining staining of gastrocneminus 18 weeks following intravenous administration of the AAV2/8 vector (1 Â 10 11 vector particles) by ILP or IV administration to GAA-KO mice. Controls were sham-treated, age-matched GAA-KO (PBS) and C57BL/6 (wild-type) mice. Arrows indicated clearance of glycogen in the myofibers. Hydrostatic ILP has been evaluated in a number of experiments involving normal rodents, dogs or primates [17] [18] [19] [21] [22] [23] [24] Generally, ILP has been deemed well tolerated, causing no apparent dysfunction and only transiently elevating serum creatine phosphokinase levels. 17, 24 Transient edema and minimal levels of myofibers damage were detected following ILP in rats and in rhesus monkeys. 22, 23 One limitation of these experiments in normal animals was the inability to demonstrate any biochemical efficacy of transgene expression, because the models used lacked any disease phenotype. Recently, a study involving the delivery of a plasmid encoding dystrophin in mdx mice demonstrated the widespread preservation of myofibers following multiple ILP administrations in association with up to 20% of normal levels of dystrophin.
The higher resistance of specific muscle groups to correction by ERT in GAA-KO mice has been attributed to both a lack of receptor-mediated uptake and abnormal trafficking of GAA by type II myofibers. 5, 25 The EDL muscle is comprised mainly of type II myofibers, 26 and the ability of the AAV vector administered herein to partially correct glycogen accumulations demonstrated a potential advantage for muscle-targeted gene therapy over ERT, in addition to decreased frequency and potentially decreased cost of gene therapy. Achieving a similar degree of correction with 30-fold lower number of AAV2/9 vector particles administered by ILP, in comparison with our earlier study of IV administration, represents an advance in the development of gene therapy for Pompe disease. 14 Several obstacles to the translation of muscle-targeted gene therapy, especially with regard to ILP, remain, including the need to transduce skeletal muscles widely with minimal risk. Recent studies of ILP in primates have illustrated how this transition might be accomplished. 24 The need for papaverine administration to achieve vasodilation and exsanguinations to eliminate blood from the vasculature prior to vector administration were deemed unnecessary, and neither method was used in the current study. In contrast to earlier studies, elevations of creatine phosphokinase reflecting muscle damage were much reduced by changing the anesthesia regimen. This latter consideration is reassuring with regard to the treatment of metabolic myopathies the predispose to myoglobinuria with accompanying risks for acute renal failure, although Pompe disease does not convey that risk. 27 Finally, the ability to perform ILP on multiple limbs could potentially treat late-onset Pompe disease that lacks significant cardiac involvement, 1,24 even in the absence of secretion of GAA from the transduced skeletal muscles or direct transduction of the cardiac muscle by muscle-targeted gene therapy.
In conclusion, we have established that musclerestricted expression of GAA in transduced myofibers will achieve long-term biochemical correction in GAA-KO mice, and that ILP will enhance AAV transduction of multiple skeletal muscles while reducing the required dosages in terms of vector particle numbers. These data justify further preclinical experiments aimed toward the development of muscle-targeted gene therapy in Pompe disease.
Materials and methods

Preparation of AAV vectors
AAV-MHCK7hGAApA contains the MHCK7 promoter, 20 the human GAA cDNA and a human growth hormone polyadenylation sequence. The vector plasmids, pAAV-MHCK7hGAApA 14 and aMHCKChAP 20 (provided by Dr Stephen Hauschka, University of Washington, Seattle, WA, USA) have been described. Briefly, 293 cells were transfected with an AAV vector, the AAV packaging plasmid 28 (courtesy of Dr James M Wilson, University of Pennsylvania, Philadelphia, PA, USA) and pAdHelper (Stratagene, La Jolla, CA, USA). Cell lysate was harvested 48 h following infection and freeze thawed three times, and isolated by sucrose cushion pelleting followed by two cesium chloride gradient centrifugation steps. AAV stocks were dialyzed against three changes of Hanks buffer, and aliquots were stored at À80 1C. The number of vector DNA containing particles was determined by DNase I digestion, DNA extraction and Southern blot analysis. All viral vector stocks were handled according to Biohazard Safety Level 2 guidelines published by the NIH.
In vivo analysis of AAV vector
The vector stocks were administered by ILP as described 17 or intravenously (via the retroorbital sinus) in 3-month-old GAA-KO mice. 29 At the indicated time points after injection, plasma or tissue samples were obtained and processed as described below. All animal procedures were done in accordance with Duke University Institutional Animal Care and Use Committee-approved guidelines.
GAA activity and glycogen content were analyzed as described. 30 Western blotting of hGAA was performed as described 31 using the hGAA monoclonal antibody (courtesy of Genzyme Corp., Framingham, MA, USA). AP staining was performed as described. 20 The enzymelinked immunosorbent assay was performed as described. 10 All samples yielded absorbance values that were within the linear range of the assay at this dilution. Real-time PCR quantification of AAV-MHCK7hGAApA has been described. 14 
Statistical analyses
Comparison of two groups was assessed by a homoscedastic Student t-test. A P-value of o0.05 indicated a significant difference between the observed values for each group. courtesy of Dr James M Wilson at the University of Pennsylvania (Philadelphia, PA, USA).
